Research Article
Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer
Table 4
Multivariate Cox regression analysis of disease outcomes according to
PRAC methylation in nonmuscle invasive bladder cancer (
).
| Variables | Recurrence | Progression | HR | 95% CI | value | HR | 95% CI | value |
| Age (<66 yrs versus ≥66 yrs) | 0.711 | 0.364–1.390 | 0.319 | 0.884 | 0.310–2.519 | 0.817 | Sex (male versus female) | 1.084 | 0.441–2.662 | 0.860 | 1.148 | 0.241–5.459 | 0.862 | Number of tumors (single versus multiple) | 1.099 | 0.568–2.127 | 0.780 | 1.178 | 0.420–3.301 | 0.755 | Tumor size (<3 cm versus ≥3 cm) | 1.270 | 0.645–2.499 | 0.490 | 4.149 | 1.184–14.540 | 0.026 | T Stage (Ta versus T1) | 0.963 | 0.437–2.122 | 0.925 | 2.028 | 0.233–17.623 | 0.521 | Grade (G1-2 versus G3) | | | 0.493 | | | 0.021 | G1 | 1 | — | — | 1 | — | — | G2 | 1.124 | 0.450–2.811 | 0.803 | 1.235 | 0.074–20.544 | 0.883 | G3 | 1.825 | 0.567–5.879 | 0.313 | 7.280 | 0.397–133.445 | 0.181 | Intravesical therapy (no versus yes) | 1.248 | 0.610–2.554 | 0.545 | 2.061 | 0.558–7.612 | 0.558 | PRAC (hypomethylation versus hypermethylation) | 2.652 | 1.241–5.667 | 0.012 | 9.531 | 1.172–77.497 | 0.035 |
|
|
HR: hazard ratio; CI: confidence interval; PRAC: prostate cancer susceptibility candidate.
|